menu
    • menu

    Company profile for LimmaTech Biologics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LimmaTech BiologicsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Grabenstrasse 3 8952 Schlieren
    Telephone
    Telephone
    +41 44 733 8585
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://lmtbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/limmatech-biologics-ag/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Global ChemShow

    Not Confirmed

    envelop Contact Supplier

    Global ChemShow

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Valneva, LimmaTech Start Ph 2 Shigella Vaccine in Infants
    Valneva, LimmaTech Start Ph 2 Shigella Vaccine in Infants

    09 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/09/3058098/0/en/Valneva-and-LimmaTech-Announce-First-Vaccination-in-Phase-2-Infant-Study-of-Tetravalent-Shigella-Vaccine-Candidate-S4V2.html

    GLOBENEWSWIRE
    09 Apr 2025
    Share Share
    LimmaTech Starts Ph 1 Trial For Staphylococcus Aureus Vaccine
    LimmaTech Starts Ph 1 Trial For Staphylococcus Aureus Vaccine

    17 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250217309427/en

    BUSINESSWIRE
    17 Feb 2025
    Share Share
    LimmaTech Awarded FDA Fast Track for Staph aureus Vaccine
    LimmaTech Awarded FDA Fast Track for Staph aureus Vaccine

    19 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241219504299/en

    BUSINESSWIRE
    19 Dec 2024
    Share Share
    Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study
    Valneva & LimmaTech Begin Phase 2b Shigella Vaccine Study

    13 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/13/2980515/0/en/Valneva-and-LimmaTech-Announce-First-Vaccination-in-Phase-2b-Human-Challenge-Study-of-Tetravalent-Shigella-Vaccine-Candidate-S4V2.html

    GLOBENEWSWIRE
    13 Nov 2024
    Share Share
    Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella
    Valneva And LimmaTech Awarded FDA Fast Track For Tetravalent Shigella

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2964323/0/en/Valneva-and-LimmaTech-Awarded-FDA-Fast-Track-Designation-for-Tetravalent-Shigella-Vaccine-Candidate-S4V.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    Valneva Pays LimmaTech $10M For Shigella Vaccine
    Valneva Pays LimmaTech $10M For Shigella Vaccine

    02 Aug 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/valneva-pays-limmatech-10m-shigella-vaccine

    FIERCE BIOTECH
    02 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search